Search company, investor...

Founded Year



Series B | Alive

Total Raised


Last Raised

$18.35M | 2 yrs ago

About Cyrus Biotechnology

Cyrus Biotechnology offers advanced software tools for protein modeling and engineering. It offers an early pipeline of programs in multiple indications to customers in biotechnology, pharmaceuticals, consumer products, chemicals, and synthetic biology. It was founded in 2014 and is based in Seattle, Washington.

Headquarters Location

3005 1st Avenue Suite 203

Seattle, Washington, 98121,

United States



Cyrus Biotechnology's Product Videos

Cyrus Biotechnology's Products & Differentiators

    Protein Design & Engineering

    Collaborative capabilities in multiple aspects of protein therapeutics discovery and development


Expert Collections containing Cyrus Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cyrus Biotechnology is included in 3 Expert Collections, including Synthetic Biology.


Synthetic Biology

67 items

Synthetic biology focused on replacing industrial and commercial materials.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Latest Cyrus Biotechnology News

OpenFold AI Research Consortium Welcomes Three New Members: UCB, NVIDIA and Valence Labs

Sep 12, 2023

OpenFold AI Research Consortium Welcomes Three New Members: UCB, NVIDIA and Valence Labs The non-profit consortium is developing publicly accessible, advanced AI-based drug discovery software tools Group aims to use AI to address ‘society’s deepest challenges’ DAVIS, Calif.--(BUSINESS WIRE)-- OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open-source software tools for biology and drug discovery, today announced the addition of three new industry members: UCB, NVIDIA, and Valence Labs (powered by Recursion ). UCB and Valence Labs expand OpenFold’s reach and support within the pharmaceutical and TechBio industries, while NVIDIA’s AI computing expertise will help accelerate the technical progress of the consortium. “AI as applied to proteins is one of the most promising areas for AI to have an impact on our day-to-day lives. The White House’s July 21 voluntary AI framework specifically mentions developing AI to address ‘society’s deepest challenges,’ giving drug discovery for oncology as an example,” said Lucas Nivon, one of the co-founders of OpenFold and CEO at Cyrus Biotechnology. “That requires efforts from the top minds in both tech and biotech, and today’s announcement brings in three key companies to help push OpenFold forward. Ultimately, the goal is that patients, especially those with unmet medical needs, can benefit from the contributions from UCB, NVIDIA and Valence Labs to support the efforts of OpenFold.” OpenFold, a consortium of academic and industry partners founded in February 2022, is a project of the Open Molecular Software Foundation , a non-profit organization advancing molecular sciences by building communities for open-source research software development. The three new members join OpenFold’s founders and existing members: Mohammed AlQuraishi’s Laboratory , Cyrus Biotechnology , Arzeda , Outpace Bio , Bayer, Basecamp Research, CHARMM Therapeutics and Dassault Systemes. OpenFold’s mission is to bring the most powerful software ever created — AI systems with the ability to engineer the molecules of life — to everyone. These tools can be used by academics, biotech and pharmaceutical companies or students learning to create the medicines of tomorrow to accelerate basic biological research and bring new cures to market that would have been impossible to discover without AI. UCB, headquartered in Brussels, Belgium, is an innovation-driven global biopharmaceutical company powered by decades of scientific excellence and pioneering research in immunology and neurology. UCB has rich experience in Computer-Aided Drug Design (CADD) across physics and AI-based approaches, as well as the expertise in applying those tools to bring treatments to market. “UCB is delighted to join the OpenFold Research Consortium, as we recognize that we can have a greater impact through open collaboration and partnerships, as well as through the use of new and advancing technologies such as artificial intelligence and computer-aided drug design. Through the application of science and technological excellence, our CADD team has enabled the discovery of some of our biologics-based treatments, and by joining the OpenFold consortium, we want to contribute to the advancement of protein structure prediction and open science,” said Dhaval Patel, chief scientific officer of UCB. “We are especially interested in AI methods to better predict protein/protein and protein/small molecule interactions. The OpenFold consortium is an excellent way for us to collaborate with other pharmaceutical and biotech companies in a pre-competitive area and with deep experts from academia to reach those goals.” NVIDIA is a full-stack computing company pioneering innovations in AI, deep learning and accelerated computing. Its technology is helping advance numerous industries, such as drug discovery , alongside other areas of biopharma. “Innovations in protein structure prediction can change the way we cure disease, produce energy and feed the world. OpenFold’s open research software development mission together with NVIDIA’s accelerated computing contributions has the potential to enable anyone and everyone to access the tools and methods needed to address these challenges,” said Anthony Costa, Group Lead for Life Sciences Developer Relations at NVIDIA. Valence Labs, which formally launched as Recursion’s machine learning research engine in July 2023, aspires to lead the industry in the development of new tools, models and benchmarks while fostering community through open science and academic research. Earlier in 2023, NVIDIA and Recursion, including Valence Labs, formed a collaboration to build foundation models for drug discovery leveraging Recursion’s proprietary datasets and NVIDIA’s computational power. “Valence Labs is honored to join OpenFold and excited to contribute to the growing movement of democratizing machine learning research for the drug discovery community,” said Daniel Cohen, President of Valence Labs. “Valence has a strong legacy of sharing our research and tools with the machine learning community, and we look forward to accelerating those efforts through the OpenFold consortium.” About OpenFold OpenFold is a non-profit artificial intelligence (AI) research consortium of academic and industry partners whose goal is to develop free and open-source software tools for biology and drug discovery, hosted as a project of the Open Molecular Software Foundation. Membership is encouraged among Biotech, Pharma, Synthetic Bio, Software/Tech, and non-profit research organizations. For more information, please visit: OpenFold Consortium Join OpenFold

Cyrus Biotechnology Frequently Asked Questions (FAQ)

  • When was Cyrus Biotechnology founded?

    Cyrus Biotechnology was founded in 2014.

  • Where is Cyrus Biotechnology's headquarters?

    Cyrus Biotechnology's headquarters is located at 3005 1st Avenue, Seattle.

  • What is Cyrus Biotechnology's latest funding round?

    Cyrus Biotechnology's latest funding round is Series B.

  • How much did Cyrus Biotechnology raise?

    Cyrus Biotechnology raised a total of $31.08M.

  • Who are the investors of Cyrus Biotechnology?

    Investors of Cyrus Biotechnology include Trinity Ventures, W Fund, OrbiMed Advisors, SpringRock Ventures, WRF Capital and 9 more.

  • Who are Cyrus Biotechnology's competitors?

    Competitors of Cyrus Biotechnology include Horizon Therapeutics and 3 more.

  • What products does Cyrus Biotechnology offer?

    Cyrus Biotechnology's products include Protein Design & Engineering and 4 more.

  • Who are Cyrus Biotechnology's customers?

    Customers of Cyrus Biotechnology include Selecta Bioscience and The Broad Institute.


Compare Cyrus Biotechnology to Competitors

Aqemia Logo

Aqemia offers drug discovery software predicting the affinity between drug candidates and therapeutic targets responsible for diseases. It uses quantum and statistical mechanics algorithms fuelling a generative artificial intelligence (AI) to design drug candidates. The company was founded in 2019 and is based in Paris, France.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine operates as a clinical-stage biotechnology company operating in pharmaceutical research and development. It offers services that include novel target discovery, generation of molecular structures with desired properties, and clinical trial analysis, enabled by advanced machine learning techniques. Its services primarily cater to the healthcare industry, with a particular emphasis on the discovery and development of innovative drugs for a range of conditions including cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It was founded in 2014 and is based in New Territories, Hong Kong.


Cradle is a company focused on the intersection of biology and artificial intelligence, operating within the biotechnology industry. The company offers a platform that aids biologists in designing improved proteins swiftly, utilizing advanced prediction algorithms and AI design suggestions. Cradle primarily serves the biotechnology sector. It was founded in 2021 and is based in Amsterdam, Netherlands.

Drais Pharmaceuticals

Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.

XtalPi Logo

XtalPi provides quantum physic-based artificial intelligence (AI) for drug research and development. It offers accurate predictions on the physicochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi was founded in 2014 and is based in Shenzhen, China.


BioMap is a pioneer in the field of life science, specifically in the domain of artificial intelligence (AI) foundation models. The company's main service involves building AI foundation models to understand and predict the behavior of life at various scales of complexity, and to generate diverse proteins quickly and accurately. These models are primarily used in the life science industry, aiding in tasks such as drug discovery, early screening and diagnosis, and other precision medicine products. It was founded in 2020 and is based in Beijing, Beijing.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.